Controlled JAGGED1 delivery induces human embryonic palate mesenchymal cells to form osteoblasts. Issue 2 (15th November 2017)

• Record Type: Journal Article
• Authors: Ndong, Jean De La Croix; Stephenson, Yvonne; Davis, Michael E.; García, Andrés J.; Goudy, Steven
• Is Part Of: Journal of biomedical materials research. Volume 106:Issue 2(2018)
• Page Start: 552
• Page End: 560
• Publication Date: 2017-11-15
• Subjects: JAGGED1 -- notch -- bone -- hydrogel; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/jbm.a.36236
• Languages: English
• ISSNs: 1549-3296

Abstract

Abstract: Osteoblast commitment and differentiation are controlled by multiple growth factors including members of the Notch signaling pathway. JAGGED1 is a cell surface ligand of the Notch pathway that is necessary for murine bone formation. The delivery of JAGGED1 to induce bone formation is complicated by its need to be presented in a bound form to allow for proper Notch receptor signaling. In this study, we investigate whether the sustained release of JAGGED1 stimulates human mesenchymal cells to commit to osteoblast cell fate using polyethylene glycol malemeide (PEG‐MAL) hydrogel delivery system. Our data demonstrated that PEG‐MAL hydrogel constructs are stable in culture for at least three weeks and maintain human mesenchymal cell viability with little cytotoxicity in vitro . JAGGED1 loaded on PEG‐MAL hydrogel (JAGGED1‐PEG‐MAL) showed continuous release from the gel for up to three weeks, with induction of Notch signaling using a CHO cell line with a Notch1 reporter construct, and qPCR gene expression analysis in vitro . Importantly, JAGGED1‐PEG‐MAL hydrogel induced mesenchymal cells towards osteogenic differentiation based on increased Alkaline phosphatase activity and osteoblast genes expression including RUNX2, ALP, COL1, and BSP. These results thus indicated that JAGGED1 delivery in vitro using PEG‐MAL hydrogel induced osteoblast commitment, suggesting that this may be a viable in vivo approach to bone regeneration. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 552–560, 2018.